OTC

Across TCGA pan-cancer cohorts, OTC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OTC data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher OTC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated OTC expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where OTC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.532	0.287	<.001	67	view →
HNSC	DFS	Median	III,IV	0.662	0.907	.002	8	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.682	.014	5	view →
LSCC	DFS	Tertile	All	0.501	0.826	.013	5	view →
LUAD	DFS	Quartile	All	0.772	0.991	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OTC–PDAC (DFS)

Open the PDAC breakdown →